Search
The Pregnancy and Early Life Immunology team's overall research vision is targeted towards understanding immunological development during early life.
We are studying immune cells from identical twins of which one suffers and one does not suffer from allergic disease to identify specific mechanisms that may play important roles in disease development.
This study is designed to identify the specific unique immune cell response that occurs in these children with recurrent disease.
Studies in Europe show exposure of pregnant women to high levels of microbial products stimulate immune function maturation in their offspring
The study aims to identify the mechanism for this so that this knowledge can be used to better treat asthma and allergies in both males and females.
This project investigates how cells of the immune system respond to substances to cause allergies to help develop new treatments.
We compared the effect of a heterologous wP/aP/aP primary series (hereafter mixed wP/aP) versus a homologous aP/aP/aP primary schedule (hereafter aP-only) on antibody responses to co-administered vaccine antigens in infants and toddlers.
Remission is the desired outcome following OIT as it allows individuals to discontinue treatment and eat the allergen freely. Early initiation of OIT in infants and toddlers has been embraced as an approach to increase the likelihood of remission. However, there is no high-quality evidence supporting younger age as an independent factor driving remission; available studies are limited by small samples of younger subjects and lack of adjustment for confounding covariates, particularly peanut-specific IgE (sIgE) levels which is closely cor
Peanut allergy is the most common food allergy in Australian school-aged children and is rarely outgrown. Access to oral immunotherapy (OIT), a disease-modifying treatment for food allergy, is limited in many regions of the world, including Australia.
Ion channel activity underlying biological processes that drive high-grade gliomas (HGG) is largely unknown. We aimed to determine the networking of ion channel genes and validate their expression within HGG patient tumors, to identify ion channel-targeting drugs that would inhibit tumor-promoting processes.